Charlie Gard Is A Prisoner Of the NHS

Charlie Gard “is ultimately a prisoner of the NHS” (the British national health service).

On the eve of a decisive day for the life of this 11-month-old baby affected by a rare disease, which the doctors at London’s Great Ormond Street Hospital wanted to unplug against the will of his family, it is the strong accusation that ‘Brought Alasdair Seton-Marsden, spokesperson of the child’s parents. If the Gard were “wealthy and not common people, baby Charlie would have already been given the opportunity to undergo alternative therapy” like the one practiced in the United States, Seton-Mardsen said.

The possibility of attempting this American therapy will now be at the center of the expertise asked by British judges to physician Michi Hirano, a professor of neurology at Columbia University in New York, who is developing this new care. Dr. Hirano is the best card for Charlie’s parents. A young neurologist, he is treating an American child at the Center for Mitochondrial and Metabolic Diseases of the Presbyterian Hospital in New York, Arturito Estopiñan, a six-year-old native of Baltimore with a disease similar to that of Charlie. He was entrusted to his care by parents Olga and Arthur, whom the doctors had announced in 2012 about the death of their child, Arturito was treated with a molecule experimentally administered only to animals, The monophosphate Desossinucleotide. This metabolic therapeutic pathway was put in place by Hirano who not only saved his life but allowed him to make immense progress. Today, this child lives at home, speaks English and Spanish taught at home, and learns to read with other children.

This story is hopeful for Charlie’s parents.

Convened by Judge Nicholas Francis of the British High Court, Michi Hirano, assisted by an international team of specialists, will have to make a decisive clinical and scientific consultation for the fate of Charlie. The American doctor arrives in London with the permission released by the American National Institute of Health (NIH), which has validated its therapeutic protocol concerning the British child’s disease, which is partly different from that of Arturito.

The verdict will be delivered on July 25th.

Recommended For You

mm

About the Author: Geoff Serka

Geoff is a former Senior Fellow at the Schuster Institute for Investigative Journalism at Brandeis University, is an award-winning travel, culture, and parenting writer. His writing has appeared in many of the nation’s most respected and credible publications, including the New York Times, the Washington Post, and on the cover of Smithsonian Magazine. A meticulous researcher who’s not afraid to be controversial, she is nationally known as a journalist who opens people’s eyes to the realities behind accepted practices in the care of children.